# Darbepoetin Alfa MDS Companion Protocol

> **NCT02175277** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 9 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT02175277
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-12
- **Primary completion:** 2017-03-20
- **Final completion:** 2017-03-20
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175277, "Darbepoetin Alfa MDS Companion Protocol". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02175277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*